about
Strategies and challenges in eliciting immunity to melanoma.The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapyCorrelation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric studyImproving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.Targeting tumours by adoptive transfer of immune cells.The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu.Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.HER-2/neu as a target for cancer vaccines.Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.CCL16 enhances the CD8+ and CD4+ T cell reactivity to human HER-2 elicited by dendritic cells loaded with rat ortholog HER-2.Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
P2860
Q30435893-03985A49-CE55-4E17-A80B-1664253328D3Q33514120-1B1D13DB-986D-41A2-9D66-7A6E2D1ABB93Q33577507-B3B9B27A-C3A3-4907-9D02-7CB584BA5815Q33638509-89547E91-1C60-4000-AE44-F18D81AA21C4Q33701600-78714E2D-64DC-4469-AA1A-65A4114B2BE3Q33820274-F0026971-9966-4E13-8EEF-35FBBF9AE2F8Q34542545-2821E692-13D8-4775-9858-607EE99174DDQ35003157-CEC2F023-50A4-42A2-9EEA-3201E78A3D29Q35838039-9CEF729E-35C4-4F5F-9358-2C9DD7843CCCQ35871310-A6C87997-A02D-47C0-A43C-666EC7644727Q36478870-AF073EA4-B258-44F6-A3EB-F15EA8112584Q36625406-990D7199-84B5-411C-8548-A7BE15BFE2B6Q36725920-6794AE91-8067-4D45-9885-AA0F6BDF9D5AQ37321696-C0B59D3A-127C-4EB9-B45B-650A39EA0E8EQ37412304-01F69BE4-93F0-43D4-B865-423CDD3701F6Q37742740-96457FA0-57C5-4716-855A-B1AF23A3338DQ37773255-3584919D-A90E-4D88-8AC0-D1A7B3CDEF2BQ39014554-032FCC6D-CFC3-41B5-9BA2-536E9AC06B72Q39895320-3337C7D7-AFA9-44A8-BC06-0C18B34239EFQ42680550-EE917D2D-5FEE-4C13-895B-393DA9074ECBQ47946808-08508618-9AFF-427F-A1B2-597E4743801E
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunogenic HER-2/neu peptides as tumor vaccines.
@ast
Immunogenic HER-2/neu peptides as tumor vaccines.
@en
type
label
Immunogenic HER-2/neu peptides as tumor vaccines.
@ast
Immunogenic HER-2/neu peptides as tumor vaccines.
@en
prefLabel
Immunogenic HER-2/neu peptides as tumor vaccines.
@ast
Immunogenic HER-2/neu peptides as tumor vaccines.
@en
P2093
P2860
P1476
Immunogenic HER-2/neu peptides as tumor vaccines.
@en
P2093
Angelos D Gritzapis
Constantin N Baxevanis
Michael Papamichail
Nectaria N Sotiriadou
Nike T Cacoullos
Panagiota A Sotiropoulou
Sonia A Perez
P2860
P2888
P356
10.1007/S00262-005-0692-3
P577
2005-10-27T00:00:00Z